Loading
After Canada created a single national review of cancer drugs in 2011, provinces agreed more often on what to fund and the median time from licence to funding fell from 522 to 393 days.
A retrospective review used Health Canada's Drug Product Database to identify new cancer drug indications between January 2003 and May 2014 and provincial formularies for funding dates and decisions to the end of 2014, in nine provinces (all except Quebec), covering 88 indications for 51 drugs. Linear and quantile regression compared time to decision before and after the pan-Canadian Oncology Drug Review began, and kappa-type statistics measured agreement between provinces.
Interprovincial concordance in funding decisions rose significantly (Brennan-Prediger coefficient 0.54 before against 0.78 after, p = 0.002), and the median time from Notice of Compliance to funding fell from 522 to 393 days (p < 0.001).
A single national review made funding of cancer drugs faster and more alike across provinces, though it still took more than a year from licence to funding.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/